Current Report Filing (8-k)
June 14 2021 - 08:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
June 14, 2021
LIPOCINE INC.
(Exact name of registrant as specified in its charter)
Commission File No. 001-36357
|
Delaware |
|
99-0370688 |
|
(State or other jurisdiction of
incorporation) |
|
(IRS Employer Identification
Number) |
|
|
|
|
675 Arapeen Drive, Suite 202
Salt Lake City, Utah 84108
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (801)
994-7383
Former name or former address, if changed since last report: Not
Applicable
______________________
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
¨ |
Written communications pursuant to
Rule 425 under the Securities Act (17 CFR 230.425) |
|
¨ |
Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
¨ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
|
¨ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the
Act:
| |
|
|
| Title
of each class |
Trading
Symbol(s) |
Name
of each exchange on which registered |
| Common
Stock, par value $0.0001 per share |
LPCN |
The
NASDAQ Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of
1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR § 240.12b-2).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act. ¨
Item 8.01 Other Events
The Company has updated its corporate presentation that it uses
when meeting with investors, analysts and others. The presentation
is filed as Exhibit 99.1.
Item 9.01 Financial Statements and
Exhibits.
(d) Exhibits
The following exhibits are filed with this report:
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
| |
|
|
LIPOCINE
INC. |
| |
|
|
|
|
| |
|
|
|
|
| Date: |
June 14, 2021 |
|
By: |
/s/ Mahesh V. Patel |
| |
|
|
|
Mahesh V. Patel |
| |
|
|
|
President and Chief Executive
Officer |
| |
|
|
|
|
| |
|
|
|
|
Lipocine (NASDAQ:LPCN)
Historical Stock Chart
From Apr 2022 to May 2022
Lipocine (NASDAQ:LPCN)
Historical Stock Chart
From May 2021 to May 2022
